Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Regulation of Food Intake

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...

Major Hormones and Their Functions

Major Hormones and Their Functions

Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preconception metabolic-bariatric surgery and child health outcomes: Identification and cohort profile of the POSIT study protocol.

medRxiv : the preprint server for health sciences·2026

Same author

Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.

Obesity pillars·2026

Same author

Effects of Glucagon-Like Peptide-1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026

Same author

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.

Obesity (Silver Spring, Md.)·2026

Same author

Relationships Between Regional and Ectopic Adiposity and Insulin Sensitivity in Early and Late Pregnancy.

Diabetes care·2026

Same author

Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.

Obesity (Silver Spring, Md.)·2026

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Serum ghrelin concentrations are increased in children with growth hormone insensitivity and decrease during

Aysin Uckun-Kitapci¹, Andrea M Haqq, Jonathan Q Purnell

¹Department of Pediatrics, Division of Endocrinology, The University of North Carolina at Chapel Hill, NC, USA. uckuna@yahoo.com

Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research

|March 5, 2008

Summary

Children with growth hormone insensitivity syndrome have higher ghrelin levels, which decrease with insulin-like growth factor-I (IGF-I) therapy. This suggests IGF-I may regulate ghrelin, impacting growth and adiposity.

More Related Videos

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Related Experiment Videos

Last Updated: Jul 7, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Area of Science:

Pediatric Endocrinology
Metabolic Disorders
Hormone Regulation

Background:

Ghrelin influences appetite, body weight, and growth hormone (GH) secretion.
Obesity and hyperinsulinemia are linked to low ghrelin, while underweight states show elevated ghrelin.
Laron syndrome (GH insensitivity syndrome, GHIS) involves GH resistance, low IGF-I, high GH, obesity, and insulin resistance.

Purpose of the Study:

To investigate ghrelin levels in children with GHIS.
To determine if insulin-like growth factor-I (IGF-I) replacement therapy affects ghrelin levels in these children.

Main Methods:

Compared fasting ghrelin levels in 13 children with GHIS and 20 age/sex/BMI-matched controls.
Monitored ghrelin, glucose, insulin, and IGF-I during IGF-I replacement therapy in GHIS subjects.

Main Results:

Children with GHIS had twofold higher fasting ghrelin levels than controls (P=0.009).
IGF-I therapy significantly reduced ghrelin levels by 56% (P<0.05).

Conclusions:

Elevated ghrelin in GHIS may contribute to increased GH secretion and adiposity.
IGF-I treatment suppresses ghrelin, indicating a potential regulatory mechanism.
This highlights a novel pathway for managing metabolic and growth abnormalities in GHIS.